Corvex Management
Corvex Management, LP is an investment firm headquartered in New York, New York that engages in value‐based investing across the capital structure in situations with identifiable catalysts. Corvex was founded in March 2011 and follows an opportunistic approach to investing with a specific focus on equity investments, special situations and distressed securities largely in North America.
View Older Stories View More Recent Stories
-
EQRx Launches “Remaking Medicine: On The Record” Investor Video Series
-
Form 13F-HR Corvex Management LP For: Sep 30
-
EQRx and NHSE Sign Memorandum of Understanding to Enter into England’s First Population Health Partnership for Cancer Drugs
-
Turning Point Therapeutics and EQRx Announce Clinical Collaboration to Evaluate Elzovantinib in Combination with Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced Non-Small Cell Lung Ca
-
EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs
-
EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs
-
EQRx and Absci Announce Partnership to Discover and Develop Next-Generation Protein-Based Drugs
-
EQRx Appoints Kathy Giusti to Board of Directors
-
EQRx Announces Presentation of Phase 3 Data Demonstrating a Progression-Free Survival Benefit with Sugemalimab Consolidation Therapy in Patients with Stage III NSCLC at ESMO Congress 2021
-
EQRx Announces Presentation of Updated Data from Pivotal Phase 3 Study of Anti-PD-L1 Antibody Sugemalimab in Combination with Chemotherapy as a First-Line Treatment for Stage IV NSCLC
-
EQRx to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
-
SomaLogic Closes Business Combination and Will Begin Trading Under the Ticker “SLGC” on the Nasdaq Stock Exchange
-
SomaLogic Closes Business Combination and Will Begin Trading Under the Ticker “SLGC” on the Nasdaq Stock Exchange
-
SomaLogic Provides 2021 Financial Guidance Exceeding Initial Merger Combination Projections
-
SomaLogic Provides 2021 Financial Guidance Exceeding Initial Merger Combination Projections
-
SomaLogic Provides 2021 Financial Guidance Exceeding Initial Merger Combination Projections
-
SomaLogic and Twist Bioscience Corporation (TWST) announce partnership to discover novel therapeutic targets and antibodies
-
SomaLogic and Twist Bioscience Corporation announce partnership to discover novel therapeutic targets and antibodies
-
SomaLogic and Twist Bioscience Corporation announce partnership to discover novel therapeutic targets and antibodies
-
EQRx Appoints Richard Buckley as Chief Corporate Affairs Officer
-
Form 13F-HR Corvex Management LP For: Jun 30
-
SomaLogic Announces Registration Statement Declared Effective and Reports 176% Y/Y Second Quarter and 187% First Half of 2021 Revenue Growth
-
SomaLogic Announces Registration Statement Declared Effective and Reports 176% Y/Y Second Quarter and 187% First Half of 2021 Revenue Growth
-
EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III (CMLTU)
-
EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination with CM Life Sciences III
-
Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company
-
Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company
-
CM Life Sciences and Sema4 Announce Release of Definitive Proxy Statement for July 21 Shareholder Meeting to Vote on Business Combination
-
Sema4 and CM Life Sciences Announce the Filing of Amended Preliminary Proxy Statement
-
Form 13F-HR Corvex Management LP For: Mar 31
-
Sema4 and CM Life Sciences Announce the Filing of the Schedule-14A Proxy Statement in Connection with the Proposed Merger
-
CM Life Sciences Announces Filing of Amended Annual Report on Form 10-K Relating to Restatement of Financial Statements in Accordance with Recent SEC Guidance
-
CM Life Sciences III Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Closing of $552 Million Initial Public Offering
-
IPO for SPAC CM Life Sciences III (CMLT) Opens at $11
-
CM Life Sciences III (CMLT) SPAC Prices 48M Shares Upsized Offering at $10
-
CM Life Sciences III Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $480 Million Initial Public Offering
-
SomaLogic to Combine with SPAC CM Life Sciences II (CMIIU)
-
SomaLogic, Leading AI-Data Driven Proteomics Platform for Advanced Research and Clinical Applications, to Combine with CM Life Sciences II, to Drive Growth and Expand Technology Platform
-
CM Life Sciences II Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Closing of $276 Million Initial Public Offering
-
CM Life Sciences II Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $240 Million Initial Public Offering
-
Form 13F-HR Corvex Management LP For: Dec 31
-
SPAC CM Life Sciences (CMLF) Surges as Cathie Wood's ARK Accumulates New 1.55M Share Stake
-
Pre-Open Stock Movers 02/10: (TLRY) (GMDA) (CMLF) Higher; (VNRX) (CPST) (XONE) Lower (more...)
-
Sema4 to Combine with SPAC, CM Life Sciences (CMLF)
-
Sema4, a Disruptive AI-driven Genomic & Clinical Data Platform Company, to Combine with CM Life Sciences to Accelerate Growth
-
Form 13F-HR Corvex Management LP For: Sep 30
-
CM Life Sciences, Inc. Announces Separate Trading of its Shares of Class A Common Stock and Warrants, on or about October 26, 2020
-
Corvex's Meister says Exelon stock can rise, calls it a defensive play
-
CM Life Sciences, Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Closing of $442.75 Million Initial Public Offering
-
CM Life Sciences, Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $385 Million Initial Public Offering
